Resumen
The separation that instructed through FABMS, already from the extracts of sponge wild cabbage sponge Crambe crambe of the Mediterranean, obtaining 2 kinds maidenly has per unit low-content ingredient crambescidin 834 (7)s of a chloro spermidine, 818 (8)s and 4 kinds are not maiden as the per unit low-content ingredient crambescidin673 (9) of derivation of spermidine, 687 (10)s, 657 (11)s and 13,14,15-isocrambescidin 657 (12) and known crambescidins (1-5) and ptilomycalin A (6). Analyze (seen Fig. 4-9) through the spectrum data, has explained their structure. In examining middle warmer claming parallelly to L1210 rat's leukaemia cell, crambescidins 834 (7)s, the cytotoxicity that 818 (8)s and 657 (11)s demonstrate is 5 times that of known crambescidin 816 (1)s. Spermidine unit or spermidine derivation per unit crambescidins demonstrates the antibacterial activity to rhodotorula.
Reivindicaciones
CLAIMS: 1. 1. Substantially pure Crambescidin 834. 2. 2. Substantially pure Crambescidin 818. 3. 3. Substantially pure Crambescidin 673. 4. 4. Substantially pure Crambescidin 687. 5. 5. Substantially pure Crambescidin 657. 6. 6. Substantially pure 13,14,15 Isocrambescidin 657. 7. 7. Substantially pure methyl Crambescidin 657. 8. 8. A pharmaceutical or veterinary composition comprising an effective antitumor amount of the substantially pure compound designated herein as Crambescidin 834 and a pharmaceutically acceptable carrier, diluent or excipient. 9. 9. A pharmaceutical or veterinary composition comprising an effective antitumor amount of the substantially pure compound designated herein as Crambescidin 818 and a pharmaceutically acceptable carrier, diluent or excipient. 10. 10. A pharmaceutical or veterinary composition comprising an effective antitumor amount of the substantially pure compound designated herein as Crambescidin 673 and a pharmaceutically acceptable carrier, diluent or excipient. 11. 11. A pharmaceutical or veterinary composition comprising an effective antitumor amount of the substantially pure compound designated herein as Crambescidin 687 and a pharmaceutically acceptable carrier, diluent or excipient. 12. 12. A pharmaceutical or veterinary composition comprising an effective antitumor amount of the substantially pure compound designated herein as Crambescidin 657 and a pharmaceutically acceptable carrier, diluent or excipient. 13. 13. A pharmaceutical or veterinary composition comprising an effective antitumor amount of the substantially pure compound designated herein as 13,14,15 Isocrambescidin 657 and a pharmaceutically acceptable carrier, diluent or excipient. 14. 14. A pharmaceutical or veterinary composition comprising an effective antitumor amount of the substantially pure compound designated herein as methyl Crambescidin 657 and a pharmaceutically acceptable carrier, diluent or excipient. 15. 15. The use for the manufacture of a medicament for the therapeutic or prophylactic treatment of a patient suffering from a mammalian tumor, of an effective antitumor amount of the substantially pure compound designated herein as Crambescidin 834 and a pharmaceutically acceptable carrier, diluent or excipient. 16. 16. The use for the manufacture of a medicament for the therapeutic or prophylactic treatment of a patient suffering from a mammalian tumor, of an effective antitumor amount of the substantially pure compound designated herein as Crambescidin 818 and a pharmaceutically acceptable carrier, diluent or excipient. 17. 17. The use for the manufacture of a medicament for the therapeutic or prophylactic treatment of a patient suffering from a mammalian tumor, of an effective antitumor amount of the substantially pure compound designated herein as Crambescidin 673 and a pharmaceutically acceptable carrier, diluent or excipient. 18. 18. The use for the manufacture of a medicament for the therapeutic or prophylactic treatment of a patient suffering from a mammalian tumor, of an effective antitumor amount of the substantially pure compound designated herein as Crambescidin 687 and a pharmaceutically acceptable carrier, diluent or excipient. 19. 19. The use for the manufacture of a medicament for the therapeutic or prophylactic treatment of a patient suffering from a mammalian tumor, of an effective antitumor amount of the substantially pure compound designated herein as Crambescidin 657 and a pharmaceutically acceptable carrier, diluent or excipient. 20. 20. The use for the manufacture of a medicament for the therapeutic or prophylactic treatment of a patient suffering from a mammalian tumor, of an effective antitumor amount of the substantially pure compound designated herein as 13,14,15 Isocrambescidin 657 and a pharmaceutically acceptable carrier, diluent or excipient. 21. 21. The use for the manufacture of a medicament for the therapeutic or prophylactic treatment of a patient suffering from a mammalian tumor, of an effective antitumor amount of the substantially pure compound designated herein as Methyl Crambescidin 657 and a pharmaceutically acceptable carrier, diluent or excipient.
